Literature DB >> 13130421

Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen.

Junko Tanuma1, Azumi Ishizaki, Hiroyuki Gatanaga, Yoshimi Kikuchi, Satoshi Kimura, Michiaki Hiroe, Shinichi Oka.   

Abstract

We describe an adult woman infected with human immunodeficiency virus type 1 (HIV-1) who developed dilated cardiomyopathy (DCM) with histologically confirmed mitochondrial damage while receiving anti-HIV-1 combination therapy that included nelfinavir, lamivudine, and zidovudine. DCM resolved after discontinuation of the regimen, and cardiac function remained normal after initiation of treatment with nelfinavir, lamivudine, and abacavir, which indicates that DCM was induced by mitochondrial toxicity, most likely caused by zidovudine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13130421     DOI: 10.1086/377609

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart.

Authors:  Delia Susan-Resiga; Alice T Bentley; Matthew D Lynx; Darcy D LaClair; Edward E McKee
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.

Authors:  Matthew D Lynx; Edward E McKee
Journal:  Biochem Pharmacol       Date:  2006-04-25       Impact factor: 5.858

3.  A case of human immunodeficiency virus-related heart failure resembling dilated cardiomyopathy but accompanied by high cardiac output.

Authors:  Noriaki Tabata; Megumi Yamamuro; Seigo Sugiyama; Michio Mizobe; Seiji Takashio; Kenichi Tsujita; Eiichiro Yamamoto; Tomoko Tanaka; Sunao Kojima; Koichi Kaikita; Shinji Tayama; Seiji Hokimoto; Chiharu Syudo; Toshikazu Miyakawa; Hiroaki Mitsuya; Hisao Ogawa
Journal:  J Cardiol Cases       Date:  2014-08-26

Review 4.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

Review 5.  HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.

Authors:  Gerald S Bloomfield; Prateeti Khazanie; Alison Morris; Cristina Rabadán-Diehl; Laura A Benjamin; David Murdoch; Virginia S Radcliff; Eric J Velazquez; Charles Hicks
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

6.  Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

Authors:  Guillaume Montastruc; Sylvie Favreliere; Agnès Sommet; Atul Pathak; Maryse Lapeyre-Mestre; Marie-Christine Perault-Pochat; Jean-Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

7.  Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.

Authors:  Judith Namuyonga; Sulaiman Lubega; Victor Musiime; Peter Lwabi; Irene Lubega
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

8.  3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity.

Authors:  Matthew D Lynx; Alice T Bentley; Edward E McKee
Journal:  Biochem Pharmacol       Date:  2006-02-10       Impact factor: 5.858

9.  Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy.

Authors:  James J Kohler; Seyed H Hosseini; William Lewis
Journal:  Chem Res Toxicol       Date:  2008-04-05       Impact factor: 3.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.